Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,899 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Deferasirox for up to 3 years leads to continued improvement of myocardial T2* in patients with β-thalassemia major.
Pennell DJ, Porter JB, Cappellini MD, Chan LL, El-Beshlawy A, Aydinok Y, Ibrahim H, Li CK, Viprakasit V, Elalfy MS, Kattamis A, Smith G, Habr D, Domokos G, Roubert B, Taher A. Pennell DJ, et al. Among authors: ibrahim h. Haematologica. 2012 Jun;97(6):842-8. doi: 10.3324/haematol.2011.049957. Epub 2012 Jan 22. Haematologica. 2012. PMID: 22271905 Free PMC article. Clinical Trial.
Efficacy of deferasirox in reducing and preventing cardiac iron overload in beta-thalassemia.
Pennell DJ, Porter JB, Cappellini MD, El-Beshlawy A, Chan LL, Aydinok Y, Elalfy MS, Sutcharitchan P, Li CK, Ibrahim H, Viprakasit V, Kattamis A, Smith G, Habr D, Domokos G, Roubert B, Taher A. Pennell DJ, et al. Among authors: ibrahim h. Blood. 2010 Mar 25;115(12):2364-71. doi: 10.1182/blood-2009-04-217455. Epub 2009 Dec 8. Blood. 2010. PMID: 19996412 Free article. Clinical Trial.
Continued improvement in myocardial T2* over two years of deferasirox therapy in β-thalassemia major patients with cardiac iron overload.
Pennell DJ, Porter JB, Cappellini MD, Chan LL, El-Beshlawy A, Aydinok Y, Ibrahim H, Li CK, Viprakasit V, Elalfy MS, Kattamis A, Smith G, Habr D, Domokos G, Roubert B, Taher A. Pennell DJ, et al. Among authors: ibrahim h. Haematologica. 2011 Jan;96(1):48-54. doi: 10.3324/haematol.2010.031468. Epub 2010 Nov 11. Haematologica. 2011. PMID: 21071497 Free PMC article.
Clinical efficacy and safety evaluation of tailoring iron chelation practice in thalassaemia patients from Asia-Pacific: a subanalysis of the EPIC study of deferasirox.
Viprakasit V, Ibrahim H, Ha SY, Ho PJ, Li CK, Chan LL, Chiu CF, Sutcharitchan P, Habr D, Domokos G, Roubert B, Xue HL, Bowden DK, Lin KH. Viprakasit V, et al. Among authors: ibrahim h. Int J Hematol. 2011 Mar;93(3):319-328. doi: 10.1007/s12185-011-0789-8. Epub 2011 Mar 4. Int J Hematol. 2011. PMID: 21374076 Clinical Trial.
Developing novel Lin28 inhibitors by computer aided drug design.
Matias-Barrios VM, Radaeva M, Rosellinny G, Jia Q, Xie N, Villanueva M, Ibrahim H, Smith J, Gleave M, Lallous N, Straus SK, Cherkasov A, Dong X. Matias-Barrios VM, et al. Among authors: ibrahim h. Cell Death Discov. 2025 Jan 12;11(1):5. doi: 10.1038/s41420-024-02281-z. Cell Death Discov. 2025. PMID: 39800739 Free PMC article.
Prevalence, Etiology and Outcomes of Native Pulmonary Regurgitation in the General Adult Population.
Naser JA, Ibrahim H, Andi K, Scott CG, Pellikka PA, Kennedy AM, Connolly HM, Nkomo VT, Enriquez-Sarano M, Pislaru SV, Warnes CA, Jain CC, Borlaug BA, Egbe AC. Naser JA, et al. Among authors: ibrahim h. Eur Heart J Cardiovasc Imaging. 2025 Jan 10:jeaf011. doi: 10.1093/ehjci/jeaf011. Online ahead of print. Eur Heart J Cardiovasc Imaging. 2025. PMID: 39792481
1,899 results